The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies
Molecular Oncology · 2025-11 · 19 (11) · 2991-2995
DOI: 10.1002/1878-0261.70149 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, online erschienen am 29.10.2025. Verfasst von Matthias Drosten und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación del Cáncer (CIC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Salamanca (USAL), Salamanca, Spain. Hauptthemen laut MEDLINE: ras Proteins, Alleles, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministry of Science, Innovation and Universities, CRIS Cancer Foundation.
Abstract (Originalsprache)
RAS oncoproteins have been considered undruggable for decades. However, recent advances have led to the development of a large variety of RAS inhibitors. While a multitude of drugs is currently under clinical evaluation, some of them have already been approved in specific contexts, leading to a continuous improvement of available therapeutic options for patients with RAS ‐mutant cancers. In this Viewpoint, we discuss different classes of RAS inhibitors, with emphasis on those that are currently tested in the clinic including allele‐specific KRAS, panKRAS, and panRAS inhibitors. We also address determinants of response to RAS inhibition such as the tumor context or potential resistance mechanisms. Finally, we provide an outlook on the future of RAS targeting, which is likely to involve combination therapies. The rapid approval of several RAS inhibitors reflects the urgency to develop novel therapeutic strategies to treat RAS ‐mutant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Investigación del Cáncer (CIC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Salamanca (USAL), Salamanca, Spain.
- Instituto de Biología Molecular y Celular del Cáncer (IBMCC), CSIC-USAL, Salamanca, Spain.
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
- Tumor Biology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
ORCID-Profile: Matthias Drosten, Mariano Barbacid
Förderung
- Spanish Ministry of Science, Innovation and Universities
- CRIS Cancer Foundation
Zitieren
APA
Drosten, M., & Barbacid, M. (2025). The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies. Molecular Oncology, 19(11), 2991-2995. https://doi.org/10.1002/1878-0261.70149
Vancouver
Drosten M, Barbacid M. The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies. Molecular Oncology. 2025;19(11):2991-2995. doi:10.1002/1878-0261.70149
BibTeX
@article{Drosten2025,
author = {Drosten, Matthias and Barbacid, Mariano},
title = {The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {11},
pages = {2991--2995},
doi = {10.1002/1878-0261.70149}
}
EUVIMED